Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Saurabh Dahiya, MD
Stanford University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University
Palo Alto, California, United States
Andrew Rezvani, MDDavid B. Miklos, MD, PhDEverett Meyer, MD, PhDJudith Shizuru, MD, PhDLaura Johnston, MDLori Muffly, MD, MSMatthew Frank, MD, PhDMelody Smith, MDPraveen Shiraz, MDRobert Lowsky, MDRobert Negrin, MDSally Arai, MDSurbhi Sidana, MDWen-Kai Weng, MD, PhDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 May 2023
- Primary completion
- 1 Apr 2038
- Completion
- 1 Apr 2038
- Last update posted
- 23 Sept 2025
- Registered enrollment
- 20
- Registry id
- NCT05794958
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.